What this study is
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
What's being tested
- Biospecimen Collection
Intervention · PROCEDURE
Undergo collection of blood and tissue samples
- Electronic Health Record Review
Intervention · OTHER
Review of medical records
Study details
- Official title
- Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
- Sponsor
- M.D. Anderson Cancer Center
- Conditions
- Colorectal Adenocarcinoma · Stage I Colorectal Cancer AJCC v8 · Stage II Colorectal Cancer AJCC v8 · Stage IIA Colorectal Cancer AJCC v8 · Stage IIB Colorectal Cancer AJCC v8 · Stage IIC Colorectal Cancer AJCC v8 · Stage III Colorectal Cancer AJCC v8 · Stage IIIA Colorectal Cancer AJCC v8 · Stage IIIB Colorectal Cancer AJCC v8 · Stage IIIC Colorectal Cancer AJCC v8 · Stage IV Colorectal Cancer AJCC v6 · Stage IVA Colorectal Cancer AJCC v8 · Stage IVB Colorectal Cancer AJCC v8 · Stage IVC Colorectal Cancer AJCC v8
- Enrolling
- 1,000 people
- Starts
- 2019-11-22
- Est. completion
- 2028-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age ≥ 18 years.
- Histological/cytological confirmation of colorectal adenocarcinoma.
- Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
- Ability to understand and the willingness to sign a written informed consent document.
- Willing to pursue standard of care surveillance post completion of curative therapies.
- Willing to provide blood samples for correlative research.
You can't join if
- Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (10)
1 openM D Anderson Cancer Center
Houston, Texas, United States
- Arvind Dasari · Contact713-792-2828adasari@mdanderson.org
- Arvind Dasari · Principal investigator
RecruitingBanner - MD Anderson Cancer Center
Gilbert, Arizona, United States
TerminatedBaptist- MD Anderson Cancer Center
Jacksonville, Florida, United States
TerminatedThe Queen's Medical Center
Honolulu, Hawaii, United States
TerminatedSt. Luke's Cancer Institute
Boise, Idaho, United States
TerminatedCooper Hospital UNIV MED CTR.
Camden, New Jersey, United States
TerminatedUT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States
TerminatedHouston Methodist Cancer Center
Houston, Texas, United States
TerminatedUT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas, United States
TerminatedBaylor Scott & White Research Institute
Temple, Texas, United States
Terminated
Study team
Sponsor
M.D. Anderson Cancer Center
Study ID PA18-1171
Principal investigator
Arvind Dasari
M.D. Anderson Cancer Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.